SCHEMBL3568658

SCHEMBL3568658

Nc1ccc(-c2ccsc2)cc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 1.00
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
BACE1 P56817 1/20 0.51
CYP2A6 P11509 5/20 0.47
CYP2E1 P05181 2/20 0.46
CYP2B6 P20813 2/20 0.46
ACMSD Q8TDX5 1/20 0.44
ERN1 O75460 1/20 0.44
PTPRC P08575 1/20 0.44
HDAC1 Q13547 3/20 0.43
CHEK1 O14757 1/20 0.42
IKBKB O14920 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LPL P06858 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
CHEK2 O96017 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468319 0.82 KCNH2 (0.69) KCNH2TDP1BACE1CYP2A6CYP2E1
SCHEMBL3134647 0.82 KCNH2 (0.69) KCNH2MEN1KMT2ABACE1CYP2A6
SCHEMBL18717328 0.82 KCNH2 (0.69) KCNH2TDP1BACE1CYP2A6CYP2E1
SCHEMBL30468982 0.81 KCNH2 (0.68) KCNH2MEN1KMT2ATDP1BACE1
SCHEMBL24359782 0.81 KCNH2 (0.68) KCNH2MEN1KMT2ATDP1BACE1
Hydrochloric Acid SCHEMBL3142023 0.80 KCNH2 (0.67) KCNH2MEN1KMT2ABACE1CYP2A6
SCHEMBL23855 0.78 TDP1 (1.00) KCNH2MEN1KMT2ATDP1ALDH1A1
SCHEMBL29349835 0.78 TDP1 (1.00) KCNH2MEN1KMT2ATDP1ALDH1A1
SCHEMBL4089548 0.77 ERN1 (0.66) KCNH2BACE1CYP2A6CYP2E1CYP2B6
SCHEMBL279003 0.77 KCNH2 (0.62) KCNH2BACE1CYP2A6CYP2E1CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834034-B2 Benzothiophene derivatives MERCK SHARP & DOHME CORP. (US) 2010-11-16 US claimed
US-20090012075-A1 Fluorinated Arylamide Derivatives MERCK SHARP & DOHME CORP. 2009-01-08 US claimed
EP-1976511-A2 FLUORINATED ARYLAMIDE DERIVATIVES Merck & Co., Inc. (US) 2008-10-08 EP claimed
WO-2007087129-A2 FLUORINATED ARYLAMIDE DERIVATIVES MERCK & CO., INC. (US) 2007-08-02 WO claimed
US-7834034-B2 Benzothiophene derivatives MERCK SHARP & DOHME CORP. (US) 2010-11-16 US disclosed
EP-1874295-A4 BENZOTHIOPHENE DERIVATIVES MERCK & CO INC (US) 2009-08-12 EP disclosed
US-20090082308-A1 Benzothiophene derivatives MERCK SHARP & DOHME LLC 2009-03-26 US disclosed
US-20090012075-A1 Fluorinated Arylamide Derivatives MERCK SHARP & DOHME CORP. 2009-01-08 US disclosed
EP-1976511-A2 FLUORINATED ARYLAMIDE DERIVATIVES Merck & Co., Inc. (US) 2008-10-08 EP disclosed
EP-1874295-A1 BENZOTHIOPHENE DERIVATIVES Merck & Co., Inc. (US) 2008-01-09 EP disclosed
WO-2007136605-A2 ARYL-FUSED SPIROCYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
WO-2007087129-A2 FLUORINATED ARYLAMIDE DERIVATIVES MERCK & CO., INC. (US) 2007-08-02 WO disclosed
WO-2006115845-A1 BENZOTHIOPHENE DERIVATIVES MERCK & CO., INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012075-A1 Fluorinated Arylamide Derivatives HDAC5, AADAC, HDAC6 KCNH2 3254/4885MEN1 2902/4885KMT2A 27/4885
US-20090082308-A1 Benzothiophene derivatives BRDT, HDAC5, BRPF3 KCNH2 4201/4885MEN1 3264/4885KMT2A 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.